# Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

> **NCT01998035** · PHASE1,PHASE2 · TERMINATED · sponsor: **Columbia University** · enrollment: 58 (actual)

## Conditions studied

- Lymphoid Malignancies
- Lymphoma
- Hodgkin Lymphoma
- Non-hodgkin Lymphoma

## Interventions

- **DRUG:** RomiDEPsin 10 MG/M2
- **DRUG:** Oral 5-Azacitidine 100 MG
- **DRUG:** Romidepsin 14 MG/M2
- **DRUG:** Oral 5-Azacitidine 200 MG
- **DRUG:** Oral 5-Azacitidine 300 MG

## Key facts

- **NCT ID:** NCT01998035
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11
- **Primary completion:** 2020-01-06
- **Final completion:** 2020-01-06
- **Target enrollment:** 58 (ACTUAL)
- **Why stopped:** PI left institution
- **Last updated:** 2024-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01998035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01998035, "Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01998035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*